## **Raquel Alves**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8425769/publications.pdf Version: 2024-02-01



PAOLIEL ALVES

#	Article	IF	CITATIONS
1	Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance. Cancers, 2021, 13, 4820.	3.7	65
2	Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma. Medical Oncology, 2015, 32, 257.	2.5	33
3	MicroRNA signature refine response prediction in CML. Scientific Reports, 2019, 9, 9666.	3.3	25
4	Chemical characterization and cytotoxic potential of an ellagitannin-enriched fraction from Fragaria vesca leaves. Arabian Journal of Chemistry, 2019, 12, 3652-3666.	4.9	20
5	Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-1±. Journal of Translational Medicine, 2020, 18, 2.	4.4	20
6	Drug transporters play a key role in the complex process of Imatinib resistance in vitro. Leukemia Research, 2015, 39, 355-360.	0.8	18
7	Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target. Medical Oncology, 2020, 37, 72.	2.5	18
8	Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines. Investigational New Drugs, 2020, 38, 369-377.	2.6	17
9	Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis. Molecular Carcinogenesis, 2017, 56, 130-148.	2.7	15
10	Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia. Medical Oncology, 2019, 36, 30.	2.5	15
11	L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells. Pathology and Oncology Research, 2016, 22, 301-309.	1.9	10
12	Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines, 2022, 10, 1158.	3.2	10
13	DNA Methylation Is Correlated with Oxidative Stress in Myelodysplastic Syndrome—Relevance as Complementary Prognostic Biomarkers. Cancers, 2021, 13, 3138.	3.7	6
14	Zinc Prevents DNA Damage in Normal Cells but Shows Genotoxic and Cytotoxic Effects in Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences, 2022, 23, 2567.	4.1	5
15	Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients. Frontiers in Cell and Developmental Biology, 2021, 9, 701328.	3.7	3
16	Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration. Journal of Investigative Surgery, 2018, 31, 243-252.	1.3	2
17	TISSULAR GROWTH FACTORS PROFILE AFTER TEDUGLUTIDE ADMINISTRATION ON AN ANIMAL MODEL OF INTESTINAL ANASTOMOSIS; PERFIL TISULAR DE FACTORES DE CRECIMIENTO POST-ADMINISTRACIÓN DE TEDUGLUTIDE EN UN MODELO ANIMAL DE ANASTOMOSIS INTESTINAL. Nutricion Hospitalaria, 2018, 35, 185-193	0.3	1
18	Can peripheral blood provide good DNA methylation biomarkers in myelodysplastic syndrome?. Journal of Molecular and Clinical Medicine, 2021, 4, 39.	0.2	1

#	Article	IF	CITATIONS
19	Gene Methylation in Myelodysplastic Syndrome – a Comparative Study Between Bone Marrow and Peripheral Blood. Annals of Oncology, 2014, 25, iv336.	1.2	0
20	Can Polymorphisms In Oxidative Stress Related Genes Be a Risk Factor For CML?. Blood, 2013, 122, 5156-5156.	1.4	0
21	Vascular Endothelial Growth Factor Expression in CD138+/CD19- and CD138+/CD19+ Plasma Cells in Monoclonal Gammopathies and Impact on Multiple Myeloma Prognosis. Blood, 2015, 126, 5342-5342.	1.4	0